Unadjusted rates of coronary heart disease death or nonfatal myocardial infarction per 1000 person-years and underlying observed event numbers in (A) men and (B) women. Unadjusted event rates are graphed by index age and low-density lipoprotein cholesterol (LDL-C) category; LDL-C ≥190 mg/dL represents the familial hypercholesterolemia (FH) phenotype, and LDL-C <130 mg/dL represents the referent. For men (A), event rates in the FH phenotype group at any given age are equivalent to those for men in the referent group who are 10 to 20 years older, indicating acceleration of coronary heart disease (CHD) risk by 10 to 20 years. For women (B), CHD risk is accelerated by 20 to 30 years. The tables below each graph show observed event numbers for the FH phenotype and referent groups by sex and index age.
Adjusted* 30-year survival free from coronary heart disease death or nonfatal myocardial infarction for index ages of (A) 20 to 29 years, (B) 30 to 39 years, (C) 40 to 49 years, (D) 50 to 59 years, (E) 60 to 69 years, and (F) 70 to 79† years. Over 30 years of follow-up, event-free survival is progressively worse for the familial hypercholesterolemia (FH) phenotype group (low-density lipoprotein cholesterol [LDL-C] ≥190 mg/dL) than for the other 2 groups. Baseline mean±SD LDL-C levels for the LDL-C <130 mg/dL (referent), 130 to 189 mg/dL, and ≥190 mg/dL (FH phenotype) groups were (A) 20 to 29 years: 96±20, 148±15, and 213±38 mg/dL; (B) 30 to 39 years: 98±20, 150±15, and 210±24 mg/dL; (C) 40 to 49 years: 100±21, 152±16, and 213±28 mg/dL; (D) 50 to 59 years: 100±26, 154±16, and 214±25 mg/dL; (E) 60 to 69 years: 101±26, 154±16, and 213±27 mg/dL; and (F) 70 to 79 years: 100±25, 153±16, and 213±22 mg/dL, respectively. *Adjusted for age, sex, race, body mass index, diabetes mellitus, smoking, systolic blood pressure, antihypertensive therapy, high-density lipoprotein cholesterol, cholesterol treatment, and cohort. †Follow-up for index age of 70 to 79 years is truncated at 23 years because of insufficient sample size thereafter.
By Amanda M.Perak, HongyanNing, Sarah D.de Ferranti, Holly C.Gooding, John T.Wilkins and Donald M.Lloyd-Jones
Observed Outcome Events and Adjusted Hazard Ratios for CHD Death or Nonfatal MI Associated With Having the FH Phenotype Using Various DefinitionsShow More
Observed Outcome Events and Adjusted Hazard Ratios for CHD Death or Nonfatal MI Associated With Having the FH Phenotype Using Various DefinitionsShow Less
